Novel CLL Drugs Jockey For Position In Tomorrow’s Revolutionized Market
Executive Summary
Gilead’s idelalisib, Roche’s Gazyva and Infinity’s IPI-145 are among a wave of new drugs promising to transform the way the disease is treated across lines of therapy.